Borgonovo Elisa, De Cristofaro Jacopo, Aletti Federico, Pedica Federica, D'Alessio Andrea
Internal Medicine, IRCCS San Raffaele Hospital, Milano, ITA.
Hematology, IRCCS San Raffaele Hospital, Milano, ITA.
Cureus. 2024 Aug 28;16(8):e68071. doi: 10.7759/cureus.68071. eCollection 2024 Aug.
Edoxaban is an oral, highly selective, direct factor X-inhibitor approved by the European Medical Agency for the prevention of stroke in non-valvular atrial fibrillation. Edoxaban is contraindicated in patients with severe hepatic insufficiency and, among adverse effects, serum bilirubin level and gamma-glutamyl transpeptidase elevation are described as common events. We report the case of an 82-year-old man with hepatocellular carcinoma who developed a fatal vanishing bile duct syndrome (VBDS) a few weeks after the administration of edoxaban for non-valvular atrial fibrillation. To the best of our knowledge, this is the first report to describe a case of acute VBDS possibly related to edoxaban.
依度沙班是一种口服的、高度选择性的直接X因子抑制剂，已获欧洲药品管理局批准用于预防非瓣膜性心房颤动患者的中风。依度沙班禁用于严重肝功能不全患者，在不良反应中，血清胆红素水平升高和γ-谷氨酰转肽酶升高被描述为常见事件。我们报告了一例82岁肝细胞癌男性患者的病例，该患者在服用依度沙班治疗非瓣膜性心房颤动几周后发生了致命的消失性胆管综合征（VBDS）。据我们所知，这是第一例描述可能与依度沙班相关的急性VBDS病例的报告。
